News

The pilot study will enroll 20 patients with existing chronic wounds, who will be monitored over a 42-day period in order to evaluate the effectiveness of dCELL Human

The foundation will now support the development of the PD01 vaccine by AFFiRiS with $475,000. AFFiRiS said that the vaccine PD01 targets the protein known as alpha-synuclein (alpha-syn),

The goal of the project is to develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers, and then use the captured

As per the terms of the acquisition, Atrium acquired Minami for a total cash consideration of EUR5.5m ($7.38m) before a revenue earn-out payment of up to EUR2m ($2.68m)

As per the agreement, Merck will provide BioPontis Alliance with guidance on Merck product portfolio priorities, thereby ensuring alignment of market demand with the discovery science that BioPontis

The aim of the collaboration is to develop a new class of medication with a novel mechanism of action for the treatment of pain and inflammatory diseases. The

The study was designed to evaluate the safety and immunomodulatory effects of SCV-07 as a monotherapy and in combination with ribavirin in relapsed HCV patients. The study results

CEL-SCI claims that Multikine is its immunotherapy developed as a first-line standard of care in treating head and neck cancer. The Phase III trial will be run at

Under the terms of the agreement, EMD Serono will be responsible for promotion, distribution, and patient support services and Ipsen will retain ownership of the product. The agreement